Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Avapritinib for GIST with a PDGFRA Exon 18 Mutation

Efficacy was evaluated in NAVIGATOR trial

13 Jan 2020
Anticancer agents & Biologic therapy;  Personalised medicine;  Sarcomas

On 9 January 2020, the US Food and Drug Administration (FDA) approved avapritinib (AYVAKITTM, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumour (GIST) harbouring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations.

Avapritinib is the first therapy approved for patients with GIST harbouring a PDGFRA exon 18 mutation.

Efficacy was investigated in NAVIGATOR (NCT02508532), a multicentre, single-arm, open-label trial enrolling 43 patients with GIST harbouring a PDGFRA exon 18 mutation, including 38 patients with PDGFRA D842V mutations. The trial initially enrolled patients at a starting dose of 400 mg orally once daily, which was later reduced to the recommended dose of 300 mg orally once daily due to toxicity.

Patients received avapritinib until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR) based on disease assessment by independent radiological review using modified RECIST v1.1 criteria. An additional efficacy outcome measure was response duration.

For patients harbouring a PDGFRA exon 18 mutation, the ORR was 84% (95% CI: 69%, 93%), with 7% complete responses (CRs) and 77% partial responses (PRs). For the subgroup of patients with PDGFRA D842V mutations, the ORR was 89% (95% CI: 75%, 97%), with 8% CRs and 82% PRs.

The median response duration was not reached with a median duration of follow-up for all patients of 10.6 months (range 0.3 to 24.9 months); 61% of the responding patients with exon 18 mutations had a response lasting 6 months or longer (31% of patients with an ongoing response were followed for less than 6 months).

The most common adverse reactions (incidence ≥ 20%) in patients who received avapritinib were oedema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhoea, hair colour changes, increased lacrimation, abdominal pain, constipation, rash and dizziness.

The recommended avapritinib dose is 300 mg orally once daily on an empty stomach, at least one hour before and two hours after a meal.

Full prescribing information for AYVAKIT are available here.

FDA granted this application priority review and Breakthrough Therapy designation. Avapritinib also received fast track and orphan drug designations.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA Oncology Center of Excellence’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.